IntelGenx (TSXV:IGX; OTCQX:IGXT) said the European Patent Office (EPO) has issued a notice of intention to grant the first key patent allowed in Europe for the company’s VersaFilm technology.
The patent is entitled, “Instantly Wettable Oral Film Dosage Form Without Surfactant or Polyalcohol.”
When granted, the patent will provide intellectual property protection for the formulation of the company’s VersaFilm technology used in its Rizaport product, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines, in Europe through 2034.
IntelGenx received a similar formulation patent covering its Rizaport VersaFilm technology in the U.S. in 2016 and has additional patent applications pending in other countries.
“This is a significant and exciting decision by the EPO, and we view this announcement as recognition of IntelGenx’s important contributions to pharmaceutical oral films,” Dr. Horst Zerbe, president and CEO, said in a statement.
